AR008615A1 - Vacuna recombinante para enfermedades causadas por organismos encapsulados, metodo para inmunizar un animal contra la pleuroneumonia y metodo para preparardicha vacuna - Google Patents

Vacuna recombinante para enfermedades causadas por organismos encapsulados, metodo para inmunizar un animal contra la pleuroneumonia y metodo para preparardicha vacuna

Info

Publication number
AR008615A1
AR008615A1 ARP970102777A ARP970102777A AR008615A1 AR 008615 A1 AR008615 A1 AR 008615A1 AR P970102777 A ARP970102777 A AR P970102777A AR P970102777 A ARP970102777 A AR P970102777A AR 008615 A1 AR008615 A1 AR 008615A1
Authority
AR
Argentina
Prior art keywords
vaccine
diseases caused
organisms
encapsulated
pleuronumonia
Prior art date
Application number
ARP970102777A
Other languages
English (en)
Original Assignee
Virginia Tech Intell Prop
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virginia Tech Intell Prop filed Critical Virginia Tech Intell Prop
Publication of AR008615A1 publication Critical patent/AR008615A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/825—Bacterial vaccine for porcine species, e.g. swine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Las vacunas contra enfermedades causadas por organismos que son encapsulados, normalmente se producen mediante la modificacion genética detales organismos, eliminando los genes que codifican para la síntesis de la cápsula o de una porcion de los mismos que sea suficiente para producirmutantes no encapsulados del organismo. A modo de ejemplo, se modifico genéticamente una cepa viva atenuada de Actinobacillus pleuropneumoniaemediante una eliminacion grande en las regionesdel cromosoma del ADN que codifica para la síntesis capsular y se produjo así una vacuna segura yefectiva contra la pleuroneumonía porcina.
ARP970102777A 1996-06-27 1997-06-24 Vacuna recombinante para enfermedades causadas por organismos encapsulados, metodo para inmunizar un animal contra la pleuroneumonia y metodo para preparardicha vacuna AR008615A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/673,814 US6086894A (en) 1996-06-27 1996-06-27 Recombinant vaccine for diseases caused by encapsulated organisms

Publications (1)

Publication Number Publication Date
AR008615A1 true AR008615A1 (es) 2000-02-09

Family

ID=24704213

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970102777A AR008615A1 (es) 1996-06-27 1997-06-24 Vacuna recombinante para enfermedades causadas por organismos encapsulados, metodo para inmunizar un animal contra la pleuroneumonia y metodo para preparardicha vacuna

Country Status (19)

Country Link
US (2) US6086894A (es)
EP (1) EP0964689A4 (es)
JP (1) JP2001522347A (es)
CN (1) CN1092069C (es)
AR (1) AR008615A1 (es)
AU (1) AU734254B2 (es)
BR (1) BR9710986A (es)
CA (1) CA2258168A1 (es)
CZ (1) CZ295438B6 (es)
HK (1) HK1020004A1 (es)
NO (1) NO986099L (es)
NZ (1) NZ333387A (es)
PL (1) PL186728B1 (es)
RU (1) RU2234941C2 (es)
SK (1) SK284610B6 (es)
TR (1) TR199802716T2 (es)
UA (1) UA70287C2 (es)
WO (1) WO1997049416A1 (es)
ZA (1) ZA975586B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69943276D1 (de) * 1998-04-02 2011-04-21 Univ Oklahoma State Chondroitin-Synthase kodierendes DNA der Pasteurella multocida und Verwendungsverfahren
US7708642B2 (en) 2001-10-15 2010-05-04 Igt Gaming device having pitch-shifted sound and music
ES2320419T3 (es) * 2002-04-05 2009-05-22 Merial Bacterias gram negativas atenuadas.
US7449178B2 (en) 2002-04-05 2008-11-11 Merial Limited Attenuated gram negative bacteria
GB0228691D0 (en) * 2002-12-09 2003-01-15 Imp College Innovations Ltd Bacterial virulence genes
ZA200509533B (en) * 2003-07-02 2007-03-28 Us Biotechnology Res And Dev Corp Acapsular P. multocida hyaE deletion mutants
JP5808671B2 (ja) * 2008-11-10 2015-11-10 ノヴォ ノルディスク アー／エス 機能グループｉｉ莢膜遺伝子クラスターを有しないｅ．ｃｏｌｉｂｌ２１株
TWI548746B (zh) * 2009-08-06 2016-09-11 英特威特國際股份有限公司 防備豬胸膜肺炎之疫苗及製備該疫苗之方法
CN106866800B (zh) * 2016-09-14 2020-08-18 四川农业大学 胸膜肺炎放线杆菌的体内诱导抗原及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US549818A (en) * 1895-11-12 Rolling-mill
AR241545A1 (es) * 1985-07-12 1992-08-31 Cornell Res Foundation Inc Un metodo para preparar una cepa de s. equi avirulenta a.t.c.c. 53186 para equinos.
WO1993010815A1 (en) * 1991-12-06 1993-06-10 Center For Innovated Technology Non-capsulated mutants of bacteria useful as vaccines
JP2717481B2 (ja) * 1992-08-25 1998-02-18 富士写真フイルム株式会社 ハロゲン化銀カラー写真感光材料

Also Published As

Publication number Publication date
US6086894A (en) 2000-07-11
AU734254B2 (en) 2001-06-07
SK177198A3 (en) 2000-03-13
RU2234941C2 (ru) 2004-08-27
CN1092069C (zh) 2002-10-09
BR9710986A (pt) 2001-12-11
ZA975586B (en) 1998-03-23
TR199802716T2 (xx) 2001-06-21
NO986099D0 (no) 1998-12-23
AU3390497A (en) 1998-01-14
HK1020004A1 (en) 2000-03-10
CA2258168A1 (en) 1997-12-31
NZ333387A (en) 2000-06-23
CZ418998A3 (cs) 1999-07-14
US6326001B1 (en) 2001-12-04
CN1223586A (zh) 1999-07-21
NO986099L (no) 1999-01-13
EP0964689A4 (en) 2004-09-08
SK284610B6 (sk) 2005-07-01
WO1997049416A1 (en) 1997-12-31
PL330863A1 (en) 1999-06-07
JP2001522347A (ja) 2001-11-13
PL186728B1 (pl) 2004-02-27
CZ295438B6 (cs) 2005-08-17
UA70287C2 (en) 2004-10-15
EP0964689A1 (en) 1999-12-22

Similar Documents

Publication Publication Date Title
EP0793717A4 (en) ORAL IMMUNIZATION BY USING TRANSGENIC PLANTS
ES2185762T3 (es) Vacunas contra la peste.
AR008615A1 (es) Vacuna recombinante para enfermedades causadas por organismos encapsulados, metodo para inmunizar un animal contra la pleuroneumonia y metodo para preparardicha vacuna
ATE33100T1 (de) Immunogenes, lebende verkapselte protozoa enthaltendes mittel.
EP0438803A3 (en) Vaccines against cancer and infectious diseases
BR9712556A (pt) Plasmìdeo, composição farmacêutica, e, processo de imunizar um indivìduo contra um antìgeno
HUP9701586A2 (hu) Javított inaktivált vakcinák
Tendler et al. Vaccination against schistosomiasis and fascioliasis with the new recombinant antigen Sm14: potential basis of a multi-valent anti-helminth vaccine?
TR200002974T2 (tr) Bruselloza karşı canlı aşı
DE68916424T2 (de) Pasteurella-impfstoff.
YU47473B (sh) Postupak za dobijanje vakcine protiv trovanja krvi živine escherichijom coli
EP0587636B1 (en) Fish vaccine for aeromonas salmonicida infection
GB9709900D0 (en) Microencapsulated DNA for vaccination and gene therapy
Liu et al. Progress in the development of a vaccine against schistosomiasis in China
Gold et al. Influence of mechanical tail-detachment techniques of schistosome cercariae on the production, viability, and infectivity of resultant schistosomula: a comparative study
SE8205247D0 (sv) Fiskvacciner
KR920703098A (ko) 신규 백신
GB9303681D0 (en) Vaccines
WO2000037649A3 (en) Dna vaccine against infectious bursal disease virus
WO2002000250A3 (en) Hiv-1 vaccines and screening methods therefor
McManus Helminth vaccines
Chatterjee et al. Acanthocheilonema viteae in Mastomys natalensis: Evaluation of efficacy of microfilarial vaccine
Seavey et al. 16 Anticancer Vaccine Strategies
Schnur Premunition, A Possible Limitation in the Prevention of the Leishmaniases by Vaccination
Ramalingaswami Vaccines for the 21st century: The big picture

Legal Events

Date Code Title Description
FB Suspension of granting procedure